Robust Kidney Abnormality Segmentation: A Validation Study of an AI-Based Framework

Kidney abnormality segmentation has important potential to enhance the clinical workflow, especially in settings requiring quantitative assessments. Kidney volume could serve as an important biomarker for renal diseases, with changes in volume correlating directly with kidney function. Currently, clinical practice often relies on subjective visual assessment for evaluating kidney size and abnormalities, including tumors and cysts, which are typically staged based on diameter, volume, and anatomical location. To support a more objective and reproducible approach, this research aims to develop a robust, thoroughly validated kidney abnormality segmentation algorithm, made publicly available for clinical and research use. Validation is conducted using both proprietary and public test datasets, with segmentation performance quantified by Dice coefficient and the 95th percentile Hausdorff distance. Furthermore, we analyze robustness across subgroups based on patient sex, age, CT contrast phases, and tumor histologic subtypes. Our findings demonstrate that our segmentation algorithm, trained exclusively on publicly available data, generalizes effectively to external test sets and outperforms existing state-of-the-art models across all tested datasets. Subgroup analyses reveal consistent high performance, indicating strong robustness and reliability. The developed algorithm and associated code are publicly accessible at https://github. Introduction Kidney cancer has a global incidence rate of approximately 400,000 new cases annually, leading to 175,000 deaths [1]. It is often detected incidentally during imaging performed for unrelated medical reasons, most often in computed tomography (CT). Treatment options for suspected malignant kidney masses include radical and partial nephrectomy [2].